Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2018
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2018
SUMMARY
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4, 19 and 4 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Respiratory which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Leukemias, Myelodysplastic Syndrome, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Atopic Dermatitis, Colorectal Cancer, Follicular Lymphoma, Hematological Tumor, Inflammation, Lung Cancer, Lymphoma, Muscular Dystrophy, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Psoriasis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Advanced Malignancy, Atherosclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pre-Diabetes/Impaired Glucose Tolerance, Prostate Cancer, Renal Cell Carcinoma, Retinal Degeneration, Substance (Drug) Abuse, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Uveal Melanoma.
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4, 19 and 4 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Respiratory which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Leukemias, Myelodysplastic Syndrome, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Atopic Dermatitis, Colorectal Cancer, Follicular Lymphoma, Hematological Tumor, Inflammation, Lung Cancer, Lymphoma, Muscular Dystrophy, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Psoriasis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Advanced Malignancy, Atherosclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pre-Diabetes/Impaired Glucose Tolerance, Prostate Cancer, Renal Cell Carcinoma, Retinal Degeneration, Substance (Drug) Abuse, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Uveal Melanoma.
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Celgene Corp
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
apabetalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birabresib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-223 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dBET-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBD-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYB-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-11313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-525762 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-417 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MZ-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-2734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-19796 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-2853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-51107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BRD4 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Facioscapulohumeral Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZBC-260 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Zenith Announces Further Advancement of Clinical Trial with ZEN-3694, a Proposed Equity Offering and an Update Webcast
May 24, 2018: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
May 07, 2018: Resverlogix Closes US$30 Million Loan
May 01, 2018: Resverlogix Advances US$30 Million Loan Closing Documentation
Apr 18, 2018: Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
Mar 28, 2018: Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
Mar 26, 2018: Promising drug may stop cancer-causing gene in its tracks
Mar 19, 2018: Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
Mar 15, 2018: TG Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting
Feb 28, 2018: NEOMED Institute Launches NEOMED Therapeutics 1 to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound
Feb 26, 2018: Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentations on its Anti-Cancer Drug Candidate CPI-0610
Jan 11, 2018: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase III BETonMACE Trial
Jan 04, 2018: SignalRx Announces In Silico Design And Discovery Of The First-In-Class HDAC6-BRD4-PI3K Epigenetic Kinase Inhibitor SRX3225
Dec 12, 2017: Natures Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent against HIV-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Celgene Corp
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
apabetalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birabresib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-223 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dBET-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBD-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYB-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-11313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-525762 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-417 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MZ-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-2734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-19796 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-2853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-51107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BRD4 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Facioscapulohumeral Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZBC-260 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Zenith Announces Further Advancement of Clinical Trial with ZEN-3694, a Proposed Equity Offering and an Update Webcast
May 24, 2018: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
May 07, 2018: Resverlogix Closes US$30 Million Loan
May 01, 2018: Resverlogix Advances US$30 Million Loan Closing Documentation
Apr 18, 2018: Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
Mar 28, 2018: Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
Mar 26, 2018: Promising drug may stop cancer-causing gene in its tracks
Mar 19, 2018: Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
Mar 15, 2018: TG Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting
Feb 28, 2018: NEOMED Institute Launches NEOMED Therapeutics 1 to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound
Feb 26, 2018: Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentations on its Anti-Cancer Drug Candidate CPI-0610
Jan 11, 2018: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase III BETonMACE Trial
Jan 04, 2018: SignalRx Announces In Silico Design And Discovery Of The First-In-Class HDAC6-BRD4-PI3K Epigenetic Kinase Inhibitor SRX3225
Dec 12, 2017: Natures Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent against HIV-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Checkpoint Therapeutics Inc, H1 2018
Pipeline by ConverGene LLC, H1 2018
Pipeline by Dybly AG, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Forma Therapeutics Inc, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Kainos Medicine Inc, H1 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Pipeline by Nuevolution AB, H1 2018
Pipeline by Plexxikon Inc, H1 2018
Pipeline by Red Glead Discovery AB, H1 2018
Pipeline by Resverlogix Corp, H1 2018
Pipeline by Trillium Therapeutics Inc, H1 2018
Pipeline by Zenith Epigenetics Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Checkpoint Therapeutics Inc, H1 2018
Pipeline by ConverGene LLC, H1 2018
Pipeline by Dybly AG, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Forma Therapeutics Inc, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Kainos Medicine Inc, H1 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Pipeline by Nuevolution AB, H1 2018
Pipeline by Plexxikon Inc, H1 2018
Pipeline by Red Glead Discovery AB, H1 2018
Pipeline by Resverlogix Corp, H1 2018
Pipeline by Trillium Therapeutics Inc, H1 2018
Pipeline by Zenith Epigenetics Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
COMPANIES MENTIONED
AstraZeneca Plc
Celgene Corp
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
COMPANIES MENTIONED
AstraZeneca Plc
Celgene Corp
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
